LOGIN  |  REGISTER
Amneal Pharmaceuticals

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 29, 2024 | Last Trade: US$2.57 0.02 0.78

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 5:00PM ET. Mr. Tucker will also be meeting with investors that day.

A webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scPharmaceuticals.com.

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead program focuses on the subcutaneous, self-administration of IV-strength treatment in heart failure. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7579
This email address is being protected from spambots. You need JavaScript enabled to view it. 

C4 Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page